Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline
Mid-Stage Milvexian Cleared First Proof-Of-Concept Hurdle
BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.
